NCT02242877已完成不适用
Observational Study in Everyday Medical Practice of the Effectiveness of Telmisartan for Treatment of Isolated Systolic Hypertension in Comparison With Systolic/Diastolic Hypertension in Patients Aged 55 or Older
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,320
- 主要终点
- Normalization of arterial systolic hypertension
研究概览
简要总结
The aim of this study is to compare the effect of treatment with telmisartan on patients in whom the systolic BP is approximately 12 weeks after starting treatment under control for the first time between patients with isolated systolic hypertension (ISH) at the beginning to patients with systolic/diastolic hypertension (SDH)
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 55, with no upper limit
- •Patient who has been treated and followed up for more than 12 months by the same general practitioner (GP)
- •Hypertension measured at least once during the past 12 months and not under control at the time of inclusion in the study:
- •isolated systolic hypertension, namely systolic blood pressure ≥ 140 mmHg and diastolic blood pressure < 90 mmHg or
- •systolic/diastolic hypertension, namely systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg; or
- •systolic blood pressure ≥ 130 and diastolic blood pressure ≥ 80 mmHg, if the patient has diabetes or chronic renal insufficiency
- •Treatment with one or more antihypertensives which remains unchanged during the month prior to collecting the data
- •Decision by the GP to add telmisartan (either in combination with hydrochlorothiazide (HCTZ) or not) to the antihypertensive treatment; this decision is made by the treating doctor regardless of participation in the study. The prescription is issued in the normal way, in accordance with the conditions set down in the marketing authorisation
- •Written informed consent of the patient to collect his/her data
排除标准
- •The patient refuses to allow his/her data to be collected
- •Change in the antihypertensive treatment during the month prior to collection of the data
- •Blood pressure under control
- •The recommended target values corresponding to control of diastolic and systolic blood pressure are important because of the diseases associated with hypertension consequently, and in order to prevent the collection process becoming too complicated, data from patients with severe renal insufficiency or with proteinuria of ≥ 1 g/L or more are not collected in the context of this study
研究组 & 干预措施
Isolated systolic hypertension
干预措施: Telmisartan (Drug)
Isolated systolic hypertension
干预措施: Telmisartan combined with hydrochlorothiazide (Drug)
Systolic and diastolic hypertension
干预措施: Telmisartan (Drug)
Systolic and diastolic hypertension
干预措施: Telmisartan combined with hydrochlorothiazide (Drug)
结局指标
主要结局
Normalization of arterial systolic hypertension
时间窗: Up to 12 weeks after start of treatment
次要结局
- Assessment of systolic blood pressure (SBP) response(Up to 12 weeks after start of treatment)
- Mean decrease in systolic blood pressure(Up to 12 weeks after start of treatment)
- Number of patients with adverse events(Up to 12 weeks)
研究者
相似试验
已完成
不适用
TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in BelgiumHypertensionNCT00886288Boehringer Ingelheim2,874
已完成
4 期
Telmisartan in Mild to Moderate Hypertensive PatientsHypertensionNCT02260089Boehringer Ingelheim134
已完成
不适用
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk HypertensivesObesityHypertensionNCT00539487Boehringer Ingelheim5,827
已完成
1 期
Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV InfectionAcute HIV InfectionHIV InfectionsNCT02170246Yale University21
已完成
4 期
INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic NephropathyDiabetic NephropathiesNCT00153088Boehringer Ingelheim527